Tempus AI reported a second-quarter revenue boost driven by growth in oncology testing, and raised full-year 2026 guidance. The company posted $382.5 million in Q2 revenue, and said its oncology testing segment grew 31% year over year, supported by continuing FDA approvals for its xT CDx platform and ongoing review of its xF liquid biopsy test. Tempus also pointed to its minimal residual disease testing expansion following its planned acquisition of Personalis for about $1.7 billion. CEO Eric Lefkofsky tied expectations for revenue uplift to upcoming approvals and the MRD portfolio’s scale-up. The results reinforce a demand-driven model for companion diagnostics and longitudinal monitoring tests, where coverage decisions and clinical adoption can directly translate into guidance revisions for commercial growth.